{"id":"https://openalex.org/W4281619002","doi":"https://doi.org/10.1200/jco.2022.40.16_suppl.tps1120","title":"ARV-471, an estrogen receptor (ER) PROTACdegrader, combined with palbociclib in advanced ER+/human epidermal growth factor receptor 2\u2013negative (HER2-) breast cancer: Phase 1b cohort (part C) of a phase 1/2 study.","display_name":"ARV-471, an estrogen receptor (ER) PROTACdegrader, combined with palbociclib in advanced ER+/human epidermal growth factor receptor 2\u2013negative (HER2-) breast cancer: Phase 1b cohort (part C) of a phase 1/2 study.","alternate_titles":[],"publication_year":2022,"publication_date":"2022-06-01","ids":{"openalex":"https://openalex.org/W4281619002","doi":"https://doi.org/10.1200/jco.2022.40.16_suppl.tps1120"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2022.40.16_suppl.tps1120","doi":"https://doi.org/10.1200/jco.2022.40.16_suppl.tps1120","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2022.40.16_suppl.tps1120","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W4281619002"],"child_works_count":0,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5003060935","display_name":"Erika Paige Hamilton","orcid":"https://orcid.org/0000-0002-1911-0336","observed_orcids":["https://orcid.org/0000-0002-1911-0336"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Erika P. Hamilton","raw_affiliation_strings":["Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN;","institution_ids":["https://openalex.org/I4210100810","https://openalex.org/I4210135086"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046583009","display_name":"Anne F. Schott","orcid":"https://orcid.org/0000-0001-9951-7269","observed_orcids":["https://orcid.org/0000-0001-9951-7269"]},"institutions":[{"id":"https://openalex.org/I4390039285","display_name":"U-M Rogel Cancer Center","ror":"https://ror.org/05asdy483","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210114445","https://openalex.org/I4390039285"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anne F. Schott","raw_affiliation_strings":["University of Michigan Rogel Cancer Center, Ann Arbor, MI;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Michigan Rogel Cancer Center, Ann Arbor, MI;","institution_ids":["https://openalex.org/I4390039285"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005007467","display_name":"Rita Nanda","orcid":"https://orcid.org/0000-0001-5248-0876","observed_orcids":["https://orcid.org/0000-0001-5248-0876"]},"institutions":[{"id":"https://openalex.org/I4210087865","display_name":"University of Chicago Medical Center","ror":"https://ror.org/0076kfe04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087865"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rita Nanda","raw_affiliation_strings":["University of Chicago Medical Center, Chicago, IL;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Chicago Medical Center, Chicago, IL;","institution_ids":["https://openalex.org/I4210087865"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074549808","display_name":"Haolan Lu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210142342","display_name":"Arvinas (United States)","ror":"https://ror.org/045jkfr03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210142342"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Haolan Lu","raw_affiliation_strings":["Arvinas, Inc., New Haven, CT;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Arvinas, Inc., New Haven, CT;","institution_ids":["https://openalex.org/I4210142342"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087161369","display_name":"Chi Keung","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210142342","display_name":"Arvinas (United States)","ror":"https://ror.org/045jkfr03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210142342"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Chi Fung Keung","raw_affiliation_strings":["Arvinas, Inc., New Haven, CT;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Arvinas, Inc., New Haven, CT;","institution_ids":["https://openalex.org/I4210142342"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006809501","display_name":"Richard W. Gedrich","orcid":"https://orcid.org/0009-0007-9623-0175","observed_orcids":["https://orcid.org/0009-0007-9623-0175"]},"institutions":[{"id":"https://openalex.org/I4210142342","display_name":"Arvinas (United States)","ror":"https://ror.org/045jkfr03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210142342"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard Gedrich","raw_affiliation_strings":["Arvinas, Inc., New Haven, CT;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Arvinas, Inc., New Haven, CT;","institution_ids":["https://openalex.org/I4210142342"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081102636","display_name":"Janaki Parameswaran","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210142342","display_name":"Arvinas (United States)","ror":"https://ror.org/045jkfr03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210142342"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Janaki Parameswaran","raw_affiliation_strings":["Arvinas, Inc., New Haven, CT;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Arvinas, Inc., New Haven, CT;","institution_ids":["https://openalex.org/I4210142342"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059240684","display_name":"Hyo Sook Han","orcid":"https://orcid.org/0000-0002-0072-0257","observed_orcids":["https://orcid.org/0000-0002-0072-0257"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hyo S. Han","raw_affiliation_strings":["Moffitt Cancer Center, Tampa, FL;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Moffitt Cancer Center, Tampa, FL;","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5068059897","display_name":"Sara Alsterlind Hurvitz","orcid":"https://orcid.org/0000-0001-7808-7191","observed_orcids":["https://orcid.org/0000-0001-7808-7191"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]},{"id":"https://openalex.org/I4390039293","display_name":"UCLA Jonsson Comprehensive Cancer Center","ror":"https://ror.org/0599cs764","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799798094","https://openalex.org/I4390039293"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sara A. Hurvitz","raw_affiliation_strings":["UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA;","institution_ids":["https://openalex.org/I161318765","https://openalex.org/I4390039293"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":8,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":71,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"40","issue":"16_suppl","first_page":"TPS1120","last_page":"TPS1120"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.9301999807357788,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.9301999807357788,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":0.06610000133514404,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.0010000000474974513,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/arv-471","display_name":"ARV-471","score":0.9990000128746033},{"id":"https://openalex.org/keywords/protac-degraders","display_name":"PROTAC degraders","score":0.7919999957084656},{"id":"https://openalex.org/keywords/estrogen-receptor-degradation","display_name":"estrogen receptor degradation","score":0.8569999933242798},{"id":"https://openalex.org/keywords/palbociclib","display_name":"palbociclib","score":0.9900000095367432},{"id":"https://openalex.org/keywords/cdk4-6-inhibitors","display_name":"CDK4/6 inhibitors","score":0.949999988079071},{"id":"https://openalex.org/keywords/er-her2-breast-cancer","display_name":"ER+/HER2- breast cancer","score":0.9120000004768372},{"id":"https://openalex.org/keywords/advanced-breast-cancer","display_name":"advanced breast cancer","score":0.843999981880188},{"id":"https://openalex.org/keywords/endocrine-therapy","display_name":"endocrine therapy","score":0.7210000157356262},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.734000027179718},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.6370000243186951},{"id":"https://openalex.org/keywords/fulvestrant","display_name":"fulvestrant","score":0.6079999804496765},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.43700000643730164},{"id":"https://openalex.org/keywords/brain-metastases","display_name":"brain metastases","score":0.4659999907016754}],"concepts":[{"id":"https://openalex.org/C2779744173","wikidata":"https://www.wikidata.org/wiki/Q15269707","display_name":"Palbociclib","level":5,"score":0.9853203296661377},{"id":"https://openalex.org/C2780482068","wikidata":"https://www.wikidata.org/wiki/Q5508491","display_name":"Fulvestrant","level":5,"score":0.9469007849693298},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8852496147155762},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.6620118618011475},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.585802435874939},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.5756953954696655},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5690953135490417},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.49575552344322205},{"id":"https://openalex.org/C84606932","wikidata":"https://www.wikidata.org/wiki/Q416496","display_name":"Estrogen receptor","level":4,"score":0.46791866421699524}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2022.40.16_suppl.tps1120","doi":"https://doi.org/10.1200/jco.2022.40.16_suppl.tps1120","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2022.40.16_suppl.tps1120","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9907000064849854}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4379285864","https://openalex.org/W4379285633","https://openalex.org/W4376613801","https://openalex.org/W4376613560","https://openalex.org/W4322772226","https://openalex.org/W4362543552","https://openalex.org/W4376613880","https://openalex.org/W4221133910","https://openalex.org/W4324131998","https://openalex.org/W4376613631"],"abstract_inverted_index":{"TPS1120":[0],"Background:":[1],"ARV-471":[2,23,54,121,152,175,203,262,274,300,346],"is":[3,118,133,250],"a":[4,80,128,134],"novel,":[5],"potent,":[6],"orally":[7,268],"bioavailable":[8],"PROteolysis":[9],"TArgeting":[10],"Chimera":[11],"(PROTAC)":[12],"protein":[13],"degrader":[14,37],"that":[15],"selectively":[16],"targets":[17],"the":[18,34,40,49,85,174,191,197,295,305,313,317,323,327],"ER.":[19],"In":[20,39],"xenograft":[21,163],"models,":[22],"demonstrated":[24],"substantially":[25,157],"greater":[26,158],"ER":[27,36],"degradation":[28],"and":[29,59,79,199,231,238,263,279,297,303,310,326,329,334,367,371],"antitumor":[30,61,343],"activity":[31,62,201,344],"compared":[32,165],"with":[33,65,140,166,181,208,253],"selective":[35],"fulvestrant.":[38],"phase":[41,51,111,192,307],"1":[42],"dose":[43,309],"escalation":[44],"portion":[45],"(Part":[46,116],"A)":[47],"of":[48,90,173,190,202,299,312,319,331,345,369],"first-in-human":[50],"1/2":[52,193],"study,":[53,194],"monotherapy":[55,122],"was":[56,101],"well":[57],"tolerated":[58],"showed":[60],"in":[63,106,123,156,162,179,206,271,358],"patients":[64,139,180,207,218],"ER+/HER2-":[66,141,227],"locally":[67],"advanced":[68,228,244],"or":[69,93,96,224],"metastatic":[70],"breast":[71,142,183,209,229],"cancer":[72,143,210,230],"who":[73,144,211],"had":[74,146],"previously":[75,212],"received":[76,213,233],"endocrine":[77,150,214,236],"therapy":[78,237,249],"cyclin-dependent":[81],"kinase":[82],"(CDK)4/6":[83],"inhibitor;":[84],"clinical":[86,200,362],"benefit":[87,363],"rate":[88,353],"(rate":[89],"confirmed":[91,226],"complete":[92],"partial":[94],"response":[95,352],"stable":[97],"disease":[98,147],"\u226524":[99],"weeks)":[100],"40%":[102],"(95%":[103],"CI:":[104],"26%\u201356%)":[105],"47":[107],"evaluable":[108],"patients.":[109],"The":[110],"2":[112,308],"VERITAC":[113],"expansion":[114],"cohort":[115],"B)":[117],"further":[119,171],"evaluating":[120],"this":[124],"patient":[125],"population.":[126],"Palbociclib,":[127],"CDK4/6":[129,247],"inhibitor,":[130],"plus":[131,153,168,176,204,301,347],"fulvestrant":[132],"standard":[135],"treatment":[136],"option":[137],"for":[138,243,281],"have":[145,222,232],"progression":[148],"on":[149,316,350],"therapy.":[151,215],"palbociclib":[154,167,177,205,264,280,302,348],"resulted":[155],"tumor":[159],"growth":[160],"inhibition":[161],"models":[164],"fulvestrant,":[169],"supporting":[170],"investigation":[172],"combination":[178,314],"ER+":[182],"cancer.":[184],"Here":[185],"we":[186],"describe":[187],"Part":[188],"C":[189],"which":[195],"evaluates":[196],"safety":[198,296],"Methods:":[216],"Eligible":[217],"(aged":[219],"\u226518":[220],"years)":[221],"histologically":[223],"cytologically":[225],"\u22651":[234],"prior":[235,240,246],"\u22642":[239],"chemotherapy":[241],"regimens":[242],"disease;":[245],"inhibitor":[248],"permitted.":[251],"Patients":[252],"known":[254],"symptomatic":[255],"brain":[256],"metastases":[257],"requiring":[258],"steroids":[259],"are":[260,292,339],"excluded.":[261],"will":[265,275],"be":[266,276],"administered":[267],"once":[269],"daily":[270],"28-day":[272],"cycles;":[273],"given":[277],"continuously":[278],"21":[282],"days":[283,287],"followed":[284],"by":[285],"7":[286],"off":[288],"treatment.":[289],"Primary":[290],"objectives":[291,338],"to":[293,340],"evaluate":[294],"tolerability":[298],"select":[304],"recommended":[306],"schedule":[311],"(based":[315,349],"incidence":[318],"dose-limiting":[320],"toxicities":[321],"during":[322],"first":[324],"cycle":[325],"frequency":[328],"severity":[330],"adverse":[332],"events":[333],"laboratory":[335],"abnormalities).":[336],"Secondary":[337],"assess":[341],"preliminary":[342],"overall":[351],"per":[354],"Response":[355],"Evaluation":[356],"Criteria":[357],"Solid":[359],"Tumors":[360],"v1.1,":[361],"rate,":[364],"progression-free":[365],"survival,":[366],"duration":[368],"response)":[370],"pharmacokinetic":[372],"parameters.":[373],"Clinical":[374],"trial":[375],"information:":[376],"NCT04072952.":[377]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W4281619002","counts_by_year":[{"year":2026,"cited_by_count":7},{"year":2025,"cited_by_count":14},{"year":2024,"cited_by_count":29},{"year":2023,"cited_by_count":16},{"year":2022,"cited_by_count":4}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2022-06-13T00:00:00"}
